Bissan Al-Lazikani, MBCS FRSB
Department of Genomic Medicine, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Director of Therapeutics Data Science, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1998 | MRC Laboratory of Molecular Biology and Newnham College, Cambridge University, Cambridge, GBR, PHD, Structural Computational Biology |
| 1995 | Imperial College, London, GBR, M.Sc, Computer Science |
Postgraduate Training
| 1999-2001 | Howard Hughes Research Fellow, Columbia University, New York City, NY |
Experience & Service
Academic Appointments
Professor, The Institute of Cancer Research, London, 2018 - 2021
Full Faculty, The Institute of Cancer Research, London, 2015 - 2021
Career Development Faculty, The Institute of Cancer Research, London, 2009 - 2005
Administrative Appointments/Responsibilities
Chair of Cancer and Drug Discovery Data Science, The Institute of Cancer Research, London, 2018 - 2021
Head of Data Science, The Institute of Cancer Research, London, 2016 - 2021
Other Appointments/Responsibilities
Chemogenomics Consultant, The European Bioinformatics Institute, Hinxton, Cambridgeshire, 2008 - 2009
Associate Director Discovery Informatics, Inpharmatica Ltd, London, 2001 - 2008
Selected Publications
Peer-Reviewed Articles
- Coker EA, Stewart A, Ozer B, Minchom A, Pickard L, Ruddle R, Carreira S, Popat S, O'Brien M, Raynaud F, de Bono J, Al-Lazikani B, Banerji U. Individualised prediction of drug response and rational combination therapy in NSCLC using artificial intelligence enabled studies of acute phosphoproteomic changes. Mol Cancer Ther 21(6):1020-1029, 2022. e-Pub 2022. PMID: 35368084.
- Dolciami D, Villasclaras-Fernandez E, Kannas C, Meniconi M, Al-Lazikani B, Antolin AA. canSAR chemistry registration and standardization pipeline. J Cheminform 14(1):28, 2022. e-Pub 2022. PMID: 35643512.
- Müller S, Ackloo S, Al Chawaf A, Al-Lazikani B, Antolin A, Baell JB, Beck H, Beedie S, Betz UAK, Bezerra GA, Brennan PE, Brown D, Brown PJ, Bullock AN, Carter AJ, Chaikuad A, Chaineau M, Ciulli A, Collins I, Dreher J, Drewry D, Edfeldt K, Edwards AM, Egner U, Frye SV, Fuchs SM, Hall MD, Hartung IV, Hillisch A, Hitchcock SH, Homan E, Kannan N, Kiefer JR, Knapp S, Kostic M, Kubicek S, Leach AR, Lindemann S, Marsden BD, Matsui H, Meier JL, Merk D, Michel M, Morgan MR, Mueller-Fahrnow A, Owen DR, Perry BG, Rosenberg SH, Saikatendu KS, Schapira M, Scholten C, Sharma S, Simeonov A, Sundström M, Superti-Furga G, Todd MH, Tredup C, Vedadi M, von Delft F, Willson TM, Winter GE, Workman P, Arrowsmith CH. Target 2035 - update on the quest for a probe for every protein. RSC Med Chem 13(1):13-21, 2022. e-Pub 2021. PMID: 35211674.
- PDBe-KB consortium. PDBe-KB: collaboratively defining the biological context of structural data. Nucleic Acids Res 50(D1):D534-D542, 2022. PMID: 34755867.
- Antolin AA, Clarke PA, Collins I, Workman P, Al-Lazikani B. Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chem Biol 28(10):1433-1445.e3, 2021. e-Pub 2021. PMID: 34077750.
- Antolin AA, Workman P, Al-Lazikani B. Public resources for chemical probes: the journey so far and the road ahead. Future Med Chem 13(8):731-747, 2021. e-Pub 2019. PMID: 31778323.
- Paschalis A, Welti J, Neeb AJ, Yuan W, Figueiredo I, Pereira R, Ferreira A, Riisnaes R, Rodrigues DN, Jiménez-Vacas JM, Kim S, Uo T, Micco PD, Tumber A, Islam MS, Moesser MA, Abboud M, Kawamura A, Gurel B, Christova R, Gil VS, Buroni L, Crespo M, Miranda S, Lambros MB, Carreira S, Tunariu N, Alimonti A, Al-Lazikani B, Schofield CJ, Plymate SR, Sharp A, de Bono JS, SU2C/PCF International Prostate Cancer Dream Team. JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. Cancer Res 81(4):1087-1100, 2021. PMID: 33822745.
- Mitsopoulos C, Di Micco P, Fernandez EV, Dolciami D, Holt E, Mica IL, Coker EA, Tym JE, Campbell J, Che KH, Ozer B, Kannas C, Antolin AA, Workman P, Al-Lazikani B. canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Res 49(D1):D1074-D1082, 2021. PMID: 33219674.
- Spitaleri A, Zia SR, Di Micco P, Al-Lazikani B, Soler MA, Rocchia W. Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case. J Phys Chem Lett 12(1):49-58, 2021. e-Pub 2020. PMID: 33300337.
- Hunter B, Reis S, Campbell D, Matharu S, Ratnakumar P, Mercuri L, Hindocha S, Kalsi H, Mayer E, Glampson B, Robinson EJ, Al-Lazikani B, Scerri L, Bloch S, Lee R. Development of a Structured Query Language and Natural Language Processing Algorithm to Identify Lung Nodules in a Cancer Centre. Front Med (Lausanne) 8:748168, 2021. e-Pub 2021. PMID: 34805217.
- Darby JF, Vidler LR, Simpson PJ, Al-Lazikani B, Matthews SJ, Sharp SY, Pearl LH, Hoelder S, Workman P. Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. Sci Rep 10(1):16000, 2020. e-Pub 2020. PMID: 32994435.
- Zhang C, Stockwell SR, Elbanna M, Ketteler R, Freeman J, Al-Lazikani B, Eccles S, De Haven Brandon A, Raynaud F, Hayes A, Clarke PA, Workman P, Mittnacht S. Correction: Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene 39(16):3411-3412, 2020. PMID: 32094403.
- Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep 10(1):2585, 2020. e-Pub 2020. PMID: 32066817.
- Antolin AA, Sanfelice D, Crisp A, Villasclaras Fernandez E, Mica IL, Chen Y, Collins I, Edwards A, Müller S, Al-Lazikani B, Workman P. The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use. Nucleic Acids Res. e-Pub 2022. PMID: 36268860.